Dyslipidaemia and metabolic syndrome in multiple myeloma (MM)
Negar Maghsoodi(St Thomas' Hospital), Martin Crook(Rutherford Appleton Laboratory), Matthew Streetly(King's College - North Carolina)
Cited by 0
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
|Leukemia|2015|256
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
|Blood Advances|2020|218
Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity Conditioning
|Transplantation and Cellular Therapy|2014|141